Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. [electronic resource]
Producer: 20120502Description: e1-8 p. digitalISSN:- 1532-0987
- Antibodies, Monoclonal -- economics
- Antibodies, Monoclonal, Humanized -- economics
- Austria -- epidemiology
- Chemoprevention
- Cost-Benefit Analysis
- Decision Trees
- Female
- Hospitalization
- Humans
- Infant
- Infant, Newborn
- Infant, Premature
- Infant, Premature, Diseases -- epidemiology
- Male
- Palivizumab
- Respiratory Syncytial Virus Infections -- epidemiology
- Respiratory Syncytial Viruses -- drug effects
- Respiratory Tract Infections -- epidemiology
- Risk
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.